Cannabinoids 2008;3(4):11-14 (9 November 2008)
Cannabinoids and schizophrenia: where is the link?
Clinic of Psychiatry, Socialpsychiatry & Psychotherapy, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany, firstname.lastname@example.org
Highlighting the association between schizophrenia and cannabis sativa and the endogenous can-nabinoid receptor system, respectively, two opposite aspects are of major relevance. On the one hand, there is substantial evidence that cannabis has to be classified as an independent risk factor for psychosis that may lead to a worse outcome of the disease. This risk seems to be increased in genetically predisposed people and may depend on the amount of cannabis used. On the other hand, there are several lines of evidence suggesting that, at least in a subgroup of patients, altera-tions in the endocannabinoid system may contribute to the pathogenesis of schizophrenia, e.g., in-creased density of cannabinoid receptor type 1 (CB1) binding and increased levels of cerebrospinal fluid (CSF) anandamide. Accordingly, beside the „dopamine hypothesis“ of schizophrenia a „can-nabinoid hypothesis“ has been suggested. Interestingly, there is a complex interaction between the dopaminergic and the cannabinoid receptor system. Thus, agents that interact with the cannabinoid receptor system such as the non-psychoactive cannabidiol (CBD) have been suggested for the treatment of psychosis.
Cannabis, THC, tetrahydrocannabinol, schizophrenia, psychosis
IACM Conference 2013
7th Conference on Cannabinoids in Medicine
The IACM Board of Directors would like to invite you to its 7th conference on Cannabinoids in September 2013 in Cologne.More
6th European Workshop on Cannabinoids
18-20 April 2013
Trinity College Dublin, Ireland
The University of British Columbia in partnership with the ICRS and the CCIC will organize “Cannabinoids in Clinical Practice” on 21 June 2013, a full day continuing medical education (CME) event.